Related Experiment Video
Updated: Jun 14, 2025
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Should We Use Aspirin or P2Y12 Inhibitor Monotherapy in Stable Ischemic Heart Disease?
Rishi Chandiramani1, Adhya Mehta2, Roger S Blumenthal1
1, 600 N Wolfe St sted 560, Baltimore, MD, 21287, USA.
For stable ischemic heart disease, clopidogrel monotherapy shows lower thrombotic and bleeding risks than aspirin. Personalized risk assessment guides future antiplatelet therapy duration after dual antiplatelet therapy.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Aspirin has been the cornerstone of secondary prevention in coronary artery disease.
- Contemporary pharmaco-invasive strategies prompt re-evaluation of aspirin's role.
Purpose of the Study:
- To review current evidence and guidelines on aspirin or P2Y12 inhibitor monotherapy in stable ischemic heart disease.
- To explore future directions in personalized bleeding and thrombotic risk assessment.
Main Methods:
- Review of recent evidence and guideline recommendations.
- Analysis of findings from the HOST-EXAM study and PANTHER meta-analysis.
Main Results:
- HOST-EXAM: Clopidogrel monotherapy showed lower thrombotic and bleeding events than aspirin.
- PANTHER meta-analysis: P2Y12 inhibitor monotherapy reduced myocardial infarction, stent thrombosis, GI bleeding, and stroke compared to aspirin.
- Both studies noted similar all-cause and cardiovascular mortality, and major bleeding rates.
Conclusions:
- Clopidogrel monotherapy is a viable alternative to aspirin for secondary prevention in stable ischemic heart disease.
- Dual antiplatelet therapy for six months post-PCI is standard, but duration should be individualized.
- Future strategies involve personalized risk assessment for tailoring antiplatelet therapy.
More Related Videos
04:30A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...